SB-649915
SB-649915 is a drug that was developed by GlaxoSmithKline for the treatment of depression and anxiety. It acts as a serotonin-norepinephrine reuptake inhibitor (SNRI) and 5-HT1A receptor agonist.
Pharmacology[edit | edit source]
SB-649915 is a potent and selective 5-HT1A receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI). It has been shown to have antidepressant and anxiolytic effects in animal studies.
Clinical trials[edit | edit source]
SB-649915 has undergone Phase I clinical trials for the treatment of depression and anxiety. However, further development of the drug was discontinued by GlaxoSmithKline for undisclosed reasons.
See also[edit | edit source]
References[edit | edit source]
| SB-649915 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
